Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics
Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of […]
GeneCentric Therapeutics Announces Commercial Availability of PurIST℠ Test for Pancreatic Cancer
GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that […]
Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced breakthrough improvements […]
Ostentus Therapeutics and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers
Ostentus Therapeutics announced today that it has entered into a second Sponsored Research Agreement with […]
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
Hinge Bio, a privately-held biotechnology company, today announced that Juha Punnonen, M.D., Ph.D. has joined […]
Genprex Receives Approval to Advance Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Biological Dynamics Case Report Published in "Frontiers in Oncology" Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions
Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for […]
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Amplia Therapeutics is pleased to announce new data showing the efficacy of its investigational FAK […]
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with […]
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer
Shattuck Labs, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more